Literature DB >> 3259176

Crystal structure of the cytokine interleukin-1 beta.

J P Priestle1, H P Schär, M G Grütter.   

Abstract

The crystal structure of human recombinant interleukin-1 beta has been determined at 3.0 A resolution by the isomorphous replacement method in conjunction with solvent flattening techniques. The model prior to refinement has a crystallographic R-factor of 42.3%. The structure is composed of 12 beta-strands forming a complex network of hydrogen bonds. The core of the structure can best be described as a tetrahedron whose edges are each formed by two antiparallel beta-strands. The interior of this structure is filled with hydrophobic side chains. There is a 3-fold repeat in the folding of the polypeptide chain. Although this folding pattern suggests gene triplication, no strong internal sequence homology between topologically corresponding residues exists. The folding topology of interleukin-1 beta is very similar to that described by McLachlan (1979) J. Mol. Biol., 133, 557-563, for soybean trypsin inhibitor.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3259176      PMCID: PMC454323          DOI: 10.1002/j.1460-2075.1988.tb02818.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  18 in total

1.  Revised nomenclature for antigen-nonspecific T-cell proliferation and helper factors.

Authors:  S B Mizel; J J Farrar
Journal:  Cell Immunol       Date:  1979-12       Impact factor: 4.868

2.  Three-dimensional structure of catalase from Penicillium vitale at 2.0 A resolution.

Authors:  B K Vainshtein; W R Melik-Adamyan; V V Barynin; A A Vagin; A I Grebenko; V V Borisov; K S Bartels; I Fita; M G Rossmann
Journal:  J Mol Biol       Date:  1986-03-05       Impact factor: 5.469

3.  Purification and partial sequence of human osteoclast-activating factor: identity with interleukin 1 beta.

Authors:  F E Dewhirst; P P Stashenko; J E Mole; T Tsurumachi
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

4.  Three-fold structural pattern in the soybean trypsin inhibitor (Kunitz).

Authors:  A D McLachlan
Journal:  J Mol Biol       Date:  1979-10-09       Impact factor: 5.469

5.  Resolution of phase ambiguity in macromolecular crystallography.

Authors:  B C Wang
Journal:  Methods Enzymol       Date:  1985       Impact factor: 1.600

6.  Purification and characterization of human interleukin-1 beta expressed in recombinant Escherichia coli.

Authors:  P Wingfield; M Payton; J Tavernier; M Barnes; A Shaw; K Rose; M G Simona; S Demczuk; K Williamson; J M Dayer
Journal:  Eur J Biochem       Date:  1986-11-03

7.  Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs.

Authors:  C J March; B Mosley; A Larsen; D P Cerretti; G Braedt; V Price; S Gillis; C S Henney; S R Kronheim; K Grabstein
Journal:  Nature       Date:  1985 Jun 20-26       Impact factor: 49.962

8.  Nucleotide sequence of human monocyte interleukin 1 precursor cDNA.

Authors:  P E Auron; A C Webb; L J Rosenwasser; S F Mucci; A Rich; S M Wolff; C A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

9.  Human interleukin 1. Purification to homogeneity.

Authors:  S R Kronheim; C J March; S K Erb; P J Conlon; D Y Mochizuki; T P Hopp
Journal:  J Exp Med       Date:  1985-03-01       Impact factor: 14.307

10.  Amino acid sequence analysis of human interleukin 1 (IL-1). Evidence for biochemically distinct forms of IL-1.

Authors:  P Cameron; G Limjuco; J Rodkey; C Bennett; J A Schmidt
Journal:  J Exp Med       Date:  1985-09-01       Impact factor: 14.307

View more
  25 in total

Review 1.  Preparation of Soluble Proteins from Escherichia coli.

Authors:  Paul T Wingfield
Journal:  Curr Protoc Protein Sci       Date:  2014-11-03

2.  An essential cell division gene of Drosophila, absent from Saccharomyces, encodes an unusual protein with tubulin-like and myosin-like peptide motifs.

Authors:  G L Miklos; M Yamamoto; R G Burns; R Maleszka
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

3.  Correlation between the 1.6 A crystal structure and mutational analysis of keratinocyte growth factor.

Authors:  T D Osslund; R Syed; E Singer; E W Hsu; R Nybo; B L Chen; T Harvey; T Arakawa; L O Narhi; A Chirino; C F Morris
Journal:  Protein Sci       Date:  1998-08       Impact factor: 6.725

4.  Design and recognition properties of a hydropathically complementary peptide to human interleukin 1 beta.

Authors:  G Fassina; G Cassani
Journal:  Biochem J       Date:  1992-03-15       Impact factor: 3.857

Review 5.  Interleukin 33 is a guardian of barriers and a local alarmin.

Authors:  Nikolas T Martin; Michael U Martin
Journal:  Nat Immunol       Date:  2016-02       Impact factor: 25.606

6.  IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo.

Authors:  Virginie Carriere; Lucie Roussel; Nathalie Ortega; Delphine-Armelle Lacorre; Laure Americh; Luc Aguilar; Gérard Bouche; Jean-Philippe Girard
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-21       Impact factor: 11.205

7.  Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist.

Authors:  J A Symons; P R Young; G W Duff
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

8.  Refinement of the structure of human basic fibroblast growth factor at 1.6 A resolution and analysis of presumed heparin binding sites by selenate substitution.

Authors:  A E Eriksson; L S Cousens; B W Matthews
Journal:  Protein Sci       Date:  1993-08       Impact factor: 6.725

9.  Chemical modification of interleukin-1 beta: biochemical characterization of a carbodiimide-catalyzed intramolecular cross-linked protein.

Authors:  A W Yem; D M Guido; W R Mathews; N D Staite; K A Richard; M D Prairie; W C Krueger; D E Epps; M R Deibel
Journal:  J Protein Chem       Date:  1992-12

10.  Stability of interleukin 1 beta (IL-1 beta) in aqueous solution: analytical methods, kinetics, products, and solution formulation implications.

Authors:  L C Gu; E A Erdös; H S Chiang; T Calderwood; K Tsai; G C Visor; J Duffy; W C Hsu; L C Foster
Journal:  Pharm Res       Date:  1991-04       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.